Nathan J Bowen to Prostatic Neoplasms
This is a "connection" page, showing publications Nathan J Bowen has written about Prostatic Neoplasms.
Connection Strength
0.382
-
Li X, Chen Y, Bai L, Zhao R, Wu Y, Xie ZR, Wu JM, Bowen NJ, Danaher A, Cook N, Li D, Qui M, Du Y, Fu H, Osunkoya AO, Kucuk O, Wu D. Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models. Br J Cancer. 2023 09; 129(5):884-894.
Score: 0.119
-
Dougan J, Hawsawi O, Burton LJ, Edwards G, Jones K, Zou J, Nagappan P, Wang G, Zhang Q, Danaher A, Bowen N, Hinton C, Odero-Marah VA. Proteomics-Metabolomics Combined Approach Identifies Peroxidasin as a Protector against Metabolic and Oxidative Stress in Prostate Cancer. Int J Mol Sci. 2019 Jun 21; 20(12).
Score: 0.089
-
Elliott B, Millena AC, Matyunina L, Zhang M, Zou J, Wang G, Zhang Q, Bowen N, Eaton V, Webb G, Thompson S, McDonald J, Khan S. Essential role of JunD in cell proliferation is mediated via MYC signaling in prostate cancer cells. Cancer Lett. 2019 04 28; 448:155-167.
Score: 0.087
-
Chinaranagari S, Sharma P, Bowen NJ, Chaudhary J. Prostate cancer epigenome. Methods Mol Biol. 2015; 1238:125-40.
Score: 0.066
-
Burton LJ, Hawsawi O, Loyd Q, Henderson V, Howard S, Harlemon M, Ragin C, Roberts R, Bowen N, Gacii A, Odero-Marah V. Association of Epithelial Mesenchymal Transition with prostate and breast health disparities. PLoS One. 2018; 13(9):e0203855.
Score: 0.021